New Collaboration Makes Brain Scanning Technology Available for Psychedelics Trials
Clerkenwell Health, a psychedelic-specialist clinical research firm, recently partnered with MYndspan, which will give medical researchers access to magnetoencephalography (MEG) scanners. MYndspan is a brain analytics firm that allows users to evaluate and monitor brain health to extend the healthy lifespan of the mind. This may be the first time MEG brain scanning technology has been availed for use in commercial clinical trials at Clerkenwell Health’s facility in central London. Clerkenwell Health has been carrying out clinical trials on psychedelics since last autumn to support the development of pharmaceuticals. Psychedelics are known to alter neural networks in the human brain,…